PDCD1 and neoplasm: MC38‐ shUSP22#1 cell was used for the construction of subcutaneous model and the results demonstrated that the combination therapy, compared to Taz or α‐PD‐1 monotherapy, significantly suppressed tumor growth, showing a synergistic anticancer effect in vivo (Figure 5C–E).